BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khatami F, Matin MM, Danesh NM, Bahrami AR, Abnous K, Taghdisi SM. Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21. Carbohydr Polym 2021;266:118111. [PMID: 34044928 DOI: 10.1016/j.carbpol.2021.118111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ashrafizadeh M, Hushmandi K, Mirzaei S, Bokaie S, Bigham A, Makvandi P, Rabiee N, Thakur VK, Kumar AP, Sharifi E, Varma RS, Aref AR, Wojnilowicz M, Zarrabi A, Karimi‐maleh H, Voelcker NH, Mostafavi E, Orive G. Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10325] [Reference Citation Analysis]
2 Akhtarkhavari T, Bahrami AR, M Matin M. Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer. Eur J Pharmacol 2022;:175233. [PMID: 36038011 DOI: 10.1016/j.ejphar.2022.175233] [Reference Citation Analysis]
3 Genedy HH, Delair T, Montembault A. Chitosan Based MicroRNA Nanocarriers. Pharmaceuticals 2022;15:1036. [DOI: 10.3390/ph15091036] [Reference Citation Analysis]
4 Jamshidi Z, Sadat Zavvar T, Ramezani M, Alibolandi M, Hadizadeh F, Abnous K, Mohammad Taghdisi S. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies. Int J Pharm 2022;:121892. [PMID: 35671850 DOI: 10.1016/j.ijpharm.2022.121892] [Reference Citation Analysis]
5 Foglizzo V, Marchiò S. Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy. Cancers (Basel) 2022;14:2473. [PMID: 35626078 DOI: 10.3390/cancers14102473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang K, Shen R, Meng T, Hu F, Yuan H. Nano-Drug Delivery Systems Based on Different Targeting Mechanisms in the Targeted Therapy of Colorectal Cancer. Molecules 2022;27:2981. [DOI: 10.3390/molecules27092981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ashrafizadeh M, Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Raei M, Hushmandi K, Zarrabi A, Voelcker NH, Aref AR, Hamblin MR, Varma RS, Samarghandian S, Arostegi IJ, Alzola M, Kumar AP, Thakur VK, Nabavi N, Makvandi P, Tay FR, Orive G. Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. Carbohydr Polym 2021;272:118491. [PMID: 34420747 DOI: 10.1016/j.carbpol.2021.118491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
8 Lohiya G, Katti DS. Mesoporous Silica Nanoparticle-Based Combination of Niclosamide and Doxorubicin: Effect of Treatment Regimens on Breast Cancer Subtypes. ACS Appl Bio Mater 2021;4:7811-24. [PMID: 35006763 DOI: 10.1021/acsabm.1c00753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]